vs
Side-by-side financial comparison of CME Group (CME) and Edwards Lifesciences (EW). Click either name above to swap in a different company.
CME Group is the larger business by last-quarter revenue ($1.9B vs $1.6B, roughly 1.1× Edwards Lifesciences). Edwards Lifesciences runs the higher net margin — 23.1% vs 0.1%, a 23.0% gap on every dollar of revenue. On growth, Edwards Lifesciences posted the faster year-over-year revenue change (16.7% vs 14.5%). Over the past eight quarters, CME Group's revenue compounded faster (10.8% CAGR vs 9.7%).
CME Group Inc. is an American financial services company based in Chicago, Illinois. It operates financial derivatives exchanges, including the Chicago Mercantile Exchange (CME), the Chicago Board of Trade (CBOT), the New York Mercantile Exchange (NYMEX), and the Commodity Exchange (COMEX). The company owns 27% of S&P Dow Jones Indices. It is the world's largest operator of financial derivatives exchanges. Its exchanges are platforms for trading in agricultural products, currencies, energy, i...
Edwards Lifesciences Corporation is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring. It developed the Sapien transcatheter aortic heart valve made of cow tissue within a balloon-expandable, cobalt-chromium frame, deployed via catheter.
CME vs EW — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $1.9B | $1.6B |
| Net Profit | $1.2M | $380.7M |
| Gross Margin | — | 78.0% |
| Operating Margin | 0.1% | 1.8% |
| Net Margin | 0.1% | 23.1% |
| Revenue YoY | 14.5% | 16.7% |
| Net Profit YoY | 20.7% | 6.8% |
| EPS (diluted) | — | $0.66 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $1.9B | $1.6B | ||
| Q4 25 | $1.6B | $1.6B | ||
| Q3 25 | $1.5B | $1.6B | ||
| Q2 25 | $1.7B | $1.5B | ||
| Q1 25 | $1.6B | $1.4B | ||
| Q4 24 | $1.5B | $1.4B | ||
| Q3 24 | $1.6B | $1.4B | ||
| Q2 24 | $1.5B | $1.4B |
| Q1 26 | $1.2M | $380.7M | ||
| Q4 25 | $1.2B | $91.2M | ||
| Q3 25 | $908.0M | $291.1M | ||
| Q2 25 | $1.0B | $333.2M | ||
| Q1 25 | $956.2M | $358.0M | ||
| Q4 24 | $874.6M | $385.6M | ||
| Q3 24 | $912.8M | $3.1B | ||
| Q2 24 | $883.2M | $366.3M |
| Q1 26 | — | 78.0% | ||
| Q4 25 | — | 78.1% | ||
| Q3 25 | — | 77.8% | ||
| Q2 25 | — | 77.5% | ||
| Q1 25 | — | 78.7% | ||
| Q4 24 | — | 78.9% | ||
| Q3 24 | — | 80.6% | ||
| Q2 24 | — | 79.9% |
| Q1 26 | 0.1% | 1.8% | ||
| Q4 25 | 61.8% | 9.6% | ||
| Q3 25 | 63.3% | 19.8% | ||
| Q2 25 | 66.7% | 26.8% | ||
| Q1 25 | 67.5% | 27.9% | ||
| Q4 24 | 62.1% | 22.6% | ||
| Q3 24 | 64.6% | 25.9% | ||
| Q2 24 | 65.3% | 26.8% |
| Q1 26 | 0.1% | 23.1% | ||
| Q4 25 | 71.7% | 5.8% | ||
| Q3 25 | 59.1% | 18.7% | ||
| Q2 25 | 60.6% | 21.7% | ||
| Q1 25 | 58.2% | 25.3% | ||
| Q4 24 | 57.3% | 27.8% | ||
| Q3 24 | 57.6% | 226.7% | ||
| Q2 24 | 57.6% | 26.7% |
| Q1 26 | — | $0.66 | ||
| Q4 25 | $3.24 | $0.16 | ||
| Q3 25 | $2.49 | $0.50 | ||
| Q2 25 | $2.81 | $0.56 | ||
| Q1 25 | $2.62 | $0.61 | ||
| Q4 24 | $2.40 | $0.65 | ||
| Q3 24 | $2.50 | $5.13 | ||
| Q2 24 | $2.42 | $0.61 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $2.4B | — |
| Total DebtLower is stronger | $3.4B | — |
| Stockholders' EquityBook value | — | — |
| Total Assets | $202.0B | — |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $2.4B | — | ||
| Q4 25 | $4.5B | $4.2B | ||
| Q3 25 | $2.6B | $3.8B | ||
| Q2 25 | $2.1B | $4.1B | ||
| Q1 25 | $1.5B | $3.9B | ||
| Q4 24 | $3.0B | $4.0B | ||
| Q3 24 | $2.4B | $4.4B | ||
| Q2 24 | $1.9B | $2.0B |
| Q1 26 | $3.4B | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | $28.7B | $10.3B | ||
| Q3 25 | $28.2B | $10.2B | ||
| Q2 25 | $27.7B | $10.5B | ||
| Q1 25 | $27.0B | $10.1B | ||
| Q4 24 | $26.5B | $10.0B | ||
| Q3 24 | $28.2B | $9.5B | ||
| Q2 24 | $27.6B | $7.4B |
| Q1 26 | $202.0B | — | ||
| Q4 25 | $198.4B | $13.7B | ||
| Q3 25 | $187.1B | $13.3B | ||
| Q2 25 | $179.9B | $13.5B | ||
| Q1 25 | $157.8B | $13.0B | ||
| Q4 24 | $137.4B | $13.1B | ||
| Q3 24 | $137.8B | $13.0B | ||
| Q2 24 | $123.4B | $10.1B |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
